Invitrogen

ErbB4 Polyclonal Antibody

ErbB4 Antibody in Immunohistochemistry (IHC)

FIGURE: 1 / 3

ErbB4 Antibody (PA5-16789) in IHC

Formalin-fixed, paraffin-embedded human breast carcinoma stained with c-erbB4 antibody using peroxidase-conjugate and AEC. Note cytoplasmic and cell membrane staining of tumor cells.

Product Image Gallery

Product Details

PA5-16789

Applications

Tested Dilution

Publications

Western Blot (WB)

2-4 µg/mL

View 1 publication 1 publication

Immunohistochemistry (IHC)

View 7 publications 7 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:50

View 1 publication 1 publication

Product Specifications

Published species

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A synthetic peptide from C-terminus of human c-erbB-4 protein

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.2 mg/mL

Storage conditions

4°C

Shipping conditions

Wet ice

AB_10987154

Product Specific Information

PA5-16789 targets HER-4 in IHC (P) and WB applications and shows reactivity with Human samples.

The PA5-16789 immunogen is a synthetic peptide from C-terminus of human c-erbB-4 protein.

Target Information

Oncogene ERBB4 (HER4) is a member of the type I receptor protein tyrosine subfamily that includes EGFR, ERBB2, and ERBB3. ERBB4 binds and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. ErbB 4 is activated by neuregulins and NTAK (neural and thymus derived activator for ErbB kinases). ErbB 4 is a receptor for heregulin and is capable of mediating HGL-stimulated tyrosine phosphorylation of itself. Like other protein kinases, ErbB 4 mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. ErbB 4 is most predominantly expressed in several breast carcinoma cell lines, and in normal skeletal muscle, heart, pituitary, brain, and cerebellum. Breast tumor cell lines T47-D, MDA-MB-453, BT-474 and H3396 are found to have the highest levels of mRNA, and intermediate levels are seen in MCF-7, MDAMB-330 and MDA-MB-361. Expression of ErbB 4 is low or absent in some breast tumor cell lines such as MDA-MB-231, MDA-MB-157, MDA-MB-468, and SKBR-3. ErbB 4 levels have been found to be elevated in certain human tumor cell lines suggesting that it may play a role in some malignancies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.

Journal of gastrointestinal oncology

Chan E,Alkhasawneh A,Duckworth LV,Aijaz T,Toro TZ,Lu X,Hughes SJ,Collinsworth A,George TJ

Published figure using ErbB4 polyclonal antibody (Product # PA5-16789) in Immunohistochemistry

Thu Dec 01 00:00:00 UTC 2016

Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Jácome AA,Wohnrath DR,Scapulatempo Neto C,Carneseca EC,Serrano SV,Viana LS,Nunes JS,Martinez EZ,Santos JS

PA5-16789 was used in immunohistochemistry to study the prognostic value of the immunohistochemical expression of HER1-4 in gastric cancer

Wed Jan 01 00:00:00 UTC 2014

Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay.

Breast cancer research and treatment

Barros FF,Abdel-Fatah TM,Moseley P,Nolan CC,Durham AC,Rakha EA,Chan S,Ellis IO,Green AR

PA5-16789 was used in immunohistochemistry to use an in situ proximity ligation assay to study the heterodimerization status of HER2 in breast cancer tissue samples

Tue Apr 01 00:00:00 UTC 2014

Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.

PloS one

Nielsen TO,Friis-Hansen L,Poulsen SS,Federspiel B,Sorensen BS

PA5-16789 was used in immunohistochemistry - paraffin section to study EGF family expression in gastrici cancer and the downregulation of HER4 and its activating ligand NRG4

Fri May 29 00:00:00 UTC 2015

Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).

Histopathology

Jay JI,Brunhoeber PS,Smith MH,Williams RR,Sugarman MC,Free HL,Tast DE

PA5-16789 was used in immunohistochemistry to study the utility of the 4B5 monoclonal antibody for clinical HER2 status determination in breast tissue expressing HER4

Fri Mar 01 00:00:00 UTC 2013

Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.

Molecular medicine (Cambridge, Mass.)

Grivas PD,Day KC,Karatsinides A,Paul A,Shakir N,Owainati I,Liebert M,Kunju LP,Thomas D,Hussain M,Day ML

PA5-16789 was used in western blot to study the efficacy and tolerability of the irreversible tyrosine kinase inhibitor dacomitinib in human bladder cancer models

Fri Nov 08 00:00:00 UTC 2013

Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

Oikawa M,Miki Y,Shimizu Y,Kumamoto H

PA5-16789 was used in immunohistochemistry to study the expression of HER family members in ameloblastomas

Wed May 01 00:00:00 UTC 2013

The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.

Scandinavian journal of clinical and laboratory investigation

Munk M,Memon A,Poulsen SS,Borre M,Nexo E,Sorensen BS

PA5-16789 was used in immunohistochemistry to study the improved survival of bladder cancer patients expressing the Jma/CYT2 isoform of HER4 in the absence of ER-alpha co-expression

Sun Sep 01 00:00:00 UTC 2013

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

Breast (Edinburgh, Scotland)

Larsen MS,Bjerre K,Lykkesfeldt AE,Giobbie-Hurder A,Laenkholm AV,Henriksen KL,Ejlertsen B,Rasmussen BB

PA5-16789 was used in immunohistochemistry to study the prognostic value of measuring activated HER receptors in patients with ER-positive breast cancer receiving adjuvant hormone therapy

Mon Oct 01 00:00:00 UTC 2012

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more